debt_leverage_profile
0.02x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct debt sensitivity; minimal long-term debt, but rising rates compress runway for cash-burning biotech/genomics SaaS firms reliant on equity markets
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Illumina sequencing platform monopoly and Taiwan/South Korea semiconductor fabrication for sequencing hardware are top two chokepoints
Inferred
Agent_Inference
international_expansion_readiness
Primarily US-revenue (~90%+); limited international exposure, minimal sovereign currency devaluation risk in top markets
Inferred
Agent_Inference
geographic_footprint
~90% US-based revenue; minimal FX devaluation risk; nascent EU/Asia exposure through biopharma partners reduces material currency impact
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Illumina represents a non-substitutable sequencing dependency exceeding 30% of operational input cost; high lock-in risk
Inferred
Agent_Inference
business_model_type_primary
Cloud migration would take 3-6 months minimum; AWS/GCP termination would severely disrupt bioinformatics pipeline delivery and customer SLAs
Inferred
Agent_Inference
business_model_type_secondary
Secondary impact: loss of cloud HPC compute would halt cancer genomics variant-calling workflows, breaching enterprise biopharma contracts
Inferred
Agent_Inference
switching_cost_profile
High API coupling risk; customers integrate NeXT Platform genomic outputs into clinical trial pipelines, creating deep workflow dependency and high switching costs
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is B2B genomic sequencing services/SaaS; no Howey Test risk—no investment contract, profit-from-others-efforts structure applies
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Handles genomic/PHI data under HIPAA primarily; GDPR exposure growing with EU biopharma clients; CCPA applicable; compliance infrastructure moderate but not fully mature
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche cancer genomics market with multiple competitors; no dominant market share position warranting regulatory scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~60-70% recurring via multi-year enterprise genomics sequencing contracts; ~30-40% transactional per-sample or project-based revenue
Inferred
Agent_Inference
monetization_vector
Per-sample sequencing fees plus multi-year enterprise platform subscriptions with biopharma and government health agency clients
Inferred
Agent_Inference
pricing_architecture
Cost-plus per-sample pricing with volume discounts; vulnerable to Illumina reagent cost inflation and competing short-read/long-read platform pricing pressure
Inferred
Agent_Inference
pricing_power_rating
Moderate; differentiated NeXT Platform offers some pricing power but commoditization risk from Illumina direct services and emerging competitors limits upside
Inferred
Agent_Inference
target_gross_margin_bracket
9.4% Gross Margin (Thin (<20%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; services are paid enterprise contracts. Churn risk exists from biopharma M&A consolidation and clinical trial completion cycles
Inferred
Agent_Inference
headcount_cost_structure
Sublinear but not fully decoupled; bioinformatics and lab ops require moderate headcount scaling; software automation reduces linearity over time
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost declines at scale due to software/bioinformatics leverage, but wet-lab sequencing operations maintain partial variable cost structure
Inferred
Agent_Inference
franchise_compliance_risk
Not a franchise model; not applicable
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely improves via biopharma enterprise land-and-expand; LTV/CAC ratio currently estimated at 3-5x, improving with platform stickiness
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; data flywheel potential exists as genomic dataset scale improves variant calling accuracy, creating indirect network value
Inferred
Agent_Inference
asset_efficiency_ratio
-24.3% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-low resilience; biopharma R&D budgets are relatively recession-resistant but VA/government contracts provide meaningful stability floor
Inferred
Agent_Inference
customer_segment_primary
Top customers: large biopharma companies (oncology clinical trials); concentration risk high—top 3 customers likely represent 50%+ of revenue
Inferred
Agent_Inference
customer_segment_secondary
Secondary segment: US Department of Veterans Affairs (MVP program); single-government-contract concentration creates material renewal and budget-cut risk
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
6.5% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0001527753
High
SEC-EDGAR
ticker
PSNL
High
SEC-EDGAR